Enovis Corporation
As of Oct 22, 2026, Enovis is in Stage 4, the downtrend phase, now in week 4 (since Sep 25, 2026). It closed at $21.59, 34.3% below its 52-week high and below its 200-day average, which is falling.
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ENOV early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ENOV among Medical Devices73rd of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
| …73 | ENOV | Stage 4 · wk 4 | 32 | +18.4% |
Enovis: quick answers
What stage is Enovis in?
As of Oct 22, 2026, Enovis (ENOV) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 25, 2026 and is in week 4. What the four stages mean
Is Enovis in an uptrend?
No. Enovis is in a Stage 4 downtrend. It trades 7.1% below its 200-day average, which is falling.
How far is Enovis from its 52-week high?
Enovis closed at $21.59 on Oct 22, 2026, 34.3% below its 52-week high of $32.87. Its 52-week low is $17.43.
How has Enovis performed over the past year?
As of Oct 22, 2026, Enovis is down 33.1% over the past year and down 18.6% so far in 2026.
Which sector and industry is Enovis in?
Enovis is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.